Alvin Chan..paktua berbangga dengan anda.. masih teguh datang ke sini.. walau anda sibuk.. walau anda perlu lakukan hal lain lebih penting.. anda sudi korban semua itu.. demi sayangkan kami bintai holders..
paktua not good. but will learn to be more good then yesterday.. with you doa..and paktua 1000% you also good person.. so please yer paktua repeat again
tolong doakan kami bintai holder berjaya capai impaian kami.. semoga bintai kembali ke paras rm1.30 minggu depan.. tak minta apa2.. minta doakan jer..
jika nak maki nak condemn bintai ke paktua terima yer..
tolong yer minta doakan jer.. semoga bintai mampu kembali cecah rm1.30 next week..
tut tut semoga mak ayah Alvin Chan dalam baik baik semoga anak2 and suami/isteri Alvin Chan baik baik semoga anda berjaya dalam trade semoga anda akan jadi sahabat baik paktua..amin
paktua berbangga dengan mobbs68.. masih teguh datang ke sini.. walau anda sibuk.. walau anda perlu lakukan hal lain lebih penting.. anda sudi korban semua itu.. demi sayangkan kami bintai holders..
paktua not good. but will learn to be more good then yesterday.. with you doa..and paktua 1000% you also good person.. so please yer paktua repeat again
tolong doakan kami bintai holder berjaya capai impaian kami.. semoga bintai kembali ke paras rm1.30 minggu depan.. tak minta apa2.. minta doakan jer..
jika nak maki nak condemn bintai ke paktua terima yer..
tolong yer minta doakan jer.. semoga bintai mampu kembali cecah rm1.30 next week..
tut tut semoga mak ayah mobbs68 dalam baik baik semoga anak2 and suami/isteri mobbs68 baik baik semoga anda berjaya dalam trade semoga anda akan jadi sahabat baik paktua..amin
Sellers going dry up soon..Solution already up.Next week the engine will start....Pak Tua im still here.Volume getting lower each days for 3 consecutive day.Tut-tut the train will start soon.Let me tell u.If best case scenario the vaccines market will be worth more thn rm 100 billion if price average rm 100 per vaccine and each people use 2.Asean got 600 million population.
Fact box: When and which Covid-19 vaccines are likely to be available in Asia
BEIJING/TOKYO/SEOUL/MANILA/TAIPEI/JAKARTA/DHAKA/HANOI (Dec 11): Trial data from Pfizer Inc with partner BioNTech SE, Moderna Inc and AstraZeneca Plc has shown their experimental vaccines are effective in preventing novel coronavirus infection. While regulatory processes are underway, few Asian countries expect to receive significant amounts of the vaccines initially. Here are estimated distribution time lines, supply deals announced and clinical trials being held in the region.
Australia The country has secured around 140 million doses: 53.8 million from AstraZeneca, 51 million from Novavax Inc, 10 million from Pfizer, and 25.5 million from distribution programme COVAX. It expects delivery of 3.8 million doses of AstraZeneca's vaccine in January and February next year and plans to begin inoculations in March.
China China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country.AstraZeneca's vaccine may be approved in China by mid-2021 and its Chinese partner Shenzhen Kangtai Biological Products Co Ltd plans annual production capacity of at least 100 million doses by the end of this year. For the Pfizer/BioNTech vaccine, a unit of Shanghai Fosun Pharmaceutical Group Co Ltd plans a Phase II trial. Tibet Rhodiola Pharmaceutical Holding Co is bringing in Russian vaccine candidate Sputnik V and plans early and mid-stage trials in China. China has also approved three vaccine candidates developed by Sinovac Biotech Ltd and state-owned China National Pharmaceutical Group (Sinopharm) for emergency use, and Sinopharm hopes its two candidates will get conditional approval for general use this year.
Japan Japan has deals to buy 120 million doses from Pfizer/BioNTech in the first half of next year and 120 million from AstraZeneca - the first 30 million of which will be shipped by March 2021 - and 250 million from Novavax. It is also in talks with Johnson & Johnson and has a deal with Shionogi & Co Ltd. Experts said vaccine makers would need to conduct at least Phase I and II trials in Japan before seeking approval for use.
South Korea The country has deals to buy 20 million doses each from AstraZeneca, Pfizer and Moderna and another 4 million doses from Johnson & Johnson's Janssen, enough to cover up to 34 million people.It will procure additional doses for 10 million people through COVAX.Inoculation is likely to start in the second quarter of next year to allow time to observe possible side effects.
India The head of the Serum Institute of India, which makes the AstraZeneca vaccine, said on Nov. 23 the positive late-state trial result of the candidate will allow it to seek emergency use approval by year-end, before securing approval for full introduction by February or March. India also expects a government-backed vaccine to be launched as early as February. It is also conducting a late-stage trial of Sputnik V.
Taiwan Taiwan aims to secure around 15 million doses initially, both via the COVAX scheme and by direct purchases from manufacturers, and may buy an additional 15 million doses. The government has said it hopes to begin vaccinations in the first quarter next year.
Malaysia The Southeast Asian nation has agreed to buy 12.8 million doses of the Pfizer vaccine, becoming the first country in the region to announce a deal with the U.S. drugmaker after some expressed reservations over the need for the ultra-cold storage that the vaccine requires. Pfizer will deliver the first batch of 1 million doses in the first quarter of next year.
The Philippines The archipelago announced a deal on Nov. 27 for 2.6 million doses of the AstraZeneca vaccine and is discussing a possible 1 million more, covering about 1% of a population of 108 million people.It is also seeking 20 million to 50 million doses from Sinovac and is in talks with others, including Pfizer.Vaccine makers can seek approval from Philippine regulators even if no clinical trial is conducted in the country.
Indonesia Southeast Asia's most populous country has secured 125.5 million doses from Sinovac, 30 million from Novavax, is in talks with AstraZeneca and Pfizer to buy 50 million doses each, and expects to get 16 million from COVAX.Indonesia is testing Sinovac's vaccine and preparing mass vaccination for medical staff and other frontline workers to start as soon as late January.
Vietnam A government official said COVAX vaccines would cover only 20% of the population and the country is likely to have a chance to secure separate deals soon, as demand is very high.
Bangladesh Bangladesh signed a deal with India's Serum Institute to buy 30 million doses of the AstraZeneca vaccine.It also expects to receive 68 million doses from global vaccine alliance GAVI at a subsidised rate, a senior health ministry official said.
FDA Pfizer vaccine approval is good for vaccine related stock That what most of the Bintai n Solution traders hoping for to goreng kau kau Should be very bullish what but why nothing going on Very disappointed hah lost of opportunity
CAIRO – 10 December 2020: The Egyptian Health Ministry on Thursday night said the first batch of a coronavirus vaccine developed by China’s Sinopharm arrived at the Cairo International Airport, coming from the UAE. The Chinese vaccine, which had been involved in clinical trials in Egypt over the past few months, has shown 86 percent efficacy against coronavirus, Health Ministry spokesman Khaled Megahed said. It has shown 99 percent efficacy in producing antibodies to the novel virus and 100 percent efficacy in preventing cases from showing moderate or severe symptoms, he added. The priority will be given to the medical staff, especially those working in isolation hospitals, as well as chest and fevers hospitals. Also, cancer patients and patients suffering from kidney failure will be prioritized, Megahed added. The vaccine is injected in the upper arm. It consists of two shots, 21 days apart. Health Minister Hala Zayed and Chinese Ambassador to Egypt Liao Liqiang have supervised the reception of the first batch at the airport.
The bubble had burst. Scheme no longer attracting. People have wise up and learned the truth. It would bleed out. Would like to say a little Prayer to those innocent lambs caught at RM1.40
Investors, please do due diligent and check all facts and news before making any decision. As of this moment, all news released has been debunked except that the ctr wishes to pay the US platform company (dotcom) a substantial upfront sum to sign an Agreement to develop a vaccine, yet to be even Pre-clinical (just drawing board formula).
Also, be well informed of the Malaysian protocol for medical approval regulations, certification of drugs and the ever important clause...Injectable drugs LICENSING which, to-date only ONE company duly approved.
Another added, "more than 600 million people of ASEAN"....daydreaming of the cash register clinking. Please respect the Governments of these countries for they are not stupid and uneducated leaders and national decision makers. Down to earth, and reality prevailing, they DO NOT need to be held ransom by this ctr for just a "possible" vaccine.
Those countries that have some faith in the Chinese Vaccine have and are current receiving supplies from China. Please, oh please, I beg you, tell me that this ctr has a hand in selling to them???? BShit.
On the 26th of March, 2020 the price of this ctr was at historical low of only RM0.06 sen. And now, at RM1.10 for no apparent changes in Income. How is that possible? The gap in falling back to earth is far too damaging.
I have been waiting and waiting for this question from you.....and now the golden and easy answer is....For the Gloves ctrs, they were suffering and trading at low prices before too. Ruberex at O.15, TG at R1.29 and Carepls. Now, as it is appeared that their perseverance and persistence paid off. THEY ARE ALREADY AN ON-GONG MANUFACTURING CONCERNS. Delivering touchable, physical and real PRODUCTS. They have Book-Orders until end of next year, 2021. TG has Sales Volumes which could generate Billions of ringgits. Their Production for 2021 is 90 Billion pieces.
Overnight, their products are in such high demand and justified requirement, it became GOLD!!!!
No comparison sir, NONE when you have nothing to sell but expecting your company's revenue to exponentially improve? If this is not just HOT air, I don't know what else to call it.
Incidentally, I do not hold any shares from Gloves ctnrs. My views are not bias and solicitous.
I say whatever I like, per se my opinions and hopefully share some insights with whoever wants to read. You don't like what you see, please skip. This is a free minded forum and except for profanities and humiliating others, upon which the Admin steps in, I have space to air my views. Also, I practice Anger Management..count to 10 and Ignore, ignore, ignore mindless and worthless remarks.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
strattegist
23,459 posts
Posted by strattegist > 2020-12-11 10:43 | Report Abuse
bravo paktua73.... thumbs up